Market Overview

Small Pharmaceuticals Rallying Following FDA Report

Related PGNX
Needham Is Bullish On Progenics Pharmaceuticals
Valeant Product Producer Progenics Announce European Approval For RELISTOR To Treat All Opioid Induced Constipation
Azedra Represents A Major Opportunity For Progenix (Seeking Alpha)

The FDA on Monday issued a briefing document ahead of its Anesthetic and Analgesic Drug Products Advisory Committee Meeting scheduled for June 11-12.

The report that new drugs designed to treat opioid-induced constipation may not require large studies to rule out heart risks before approval. According to the report, the length of the studies may be "impractical" given the purpose of the drugs.

The following stocks stand to be affected by the decision and have been reacting to the report.

  • Progenics Pharmaceuticals (NASDAQ: PGNX) up ~9 percent to ~$3.80
  • Nektar Therapeutics (NASDAQ: NKTR) up ~8 percent to ~$12.10
  • Sucampo Pharmaceuticals (NASDAQ: SCMP) up ~3 percent to ~$7.45
  • Synergy Pharmaceuticals (NASDAQ: SGYP) up ~5 percent to $4.45

Posted-In: News FDA


Related Articles (NKTR + PGNX)

Around the Web, We're Loving...

Get Benzinga's Newsletters